368 related articles for article (PubMed ID: 25495193)
1. Metabolic characterization of triple negative breast cancer.
Cao MD; Lamichhane S; Lundgren S; Bofin A; Fjøsne H; Giskeødegård GF; Bathen TF
BMC Cancer; 2014 Dec; 14():941. PubMed ID: 25495193
[TBL] [Abstract][Full Text] [Related]
2. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
[TBL] [Abstract][Full Text] [Related]
3. Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models.
Moestue SA; Borgan E; Huuse EM; Lindholm EM; Sitter B; Børresen-Dale AL; Engebraaten O; Maelandsmo GM; Gribbestad IS
BMC Cancer; 2010 Aug; 10():433. PubMed ID: 20716336
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Response to Everolimus in Patient-Derived Triple-Negative Breast Cancer Xenografts.
Euceda LR; Hill DK; Stokke E; Hatem R; El Botty R; Bièche I; Marangoni E; Bathen TF; Moestue SA
J Proteome Res; 2017 May; 16(5):1868-1879. PubMed ID: 28290700
[TBL] [Abstract][Full Text] [Related]
5. Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease.
Kanaan YM; Sampey BP; Beyene D; Esnakula AK; Naab TJ; Ricks-Santi LJ; Dasi S; Day A; Blackman KW; Frederick W; Copeland RL; Gabrielson E; Dewitty RL
Cancer Genomics Proteomics; 2014; 11(6):279-94. PubMed ID: 25422359
[TBL] [Abstract][Full Text] [Related]
6. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
[TBL] [Abstract][Full Text] [Related]
7. Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling.
Cao MD; Sitter B; Bathen TF; Bofin A; Lønning PE; Lundgren S; Gribbestad IS
NMR Biomed; 2012 Feb; 25(2):369-78. PubMed ID: 21823183
[TBL] [Abstract][Full Text] [Related]
8. Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer.
Apaya MK; Shiau JY; Liao GS; Liang YJ; Chen CW; Yang HC; Chu CH; Yu JC; Shyur LF
J Exp Clin Cancer Res; 2019 May; 38(1):187. PubMed ID: 31072371
[TBL] [Abstract][Full Text] [Related]
9. A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease.
Kaur P; Nagaraja GM; Zheng H; Gizachew D; Galukande M; Krishnan S; Asea A
BMC Cancer; 2012 Mar; 12():120. PubMed ID: 22452810
[TBL] [Abstract][Full Text] [Related]
10. Triple-Negative Breast Cancer in Ghanaian Women: The Korle Bu Teaching Hospital Experience.
Der EM; Gyasi RK; Tettey Y; Edusei L; Bayor MT; Jiagge E; Gyakobo M; Merajver SD; Newman LA
Breast J; 2015; 21(6):627-33. PubMed ID: 26547900
[TBL] [Abstract][Full Text] [Related]
11. Lactate and glycine-potential MR biomarkers of prognosis in estrogen receptor-positive breast cancers.
Giskeødegård GF; Lundgren S; Sitter B; Fjøsne HE; Postma G; Buydens LM; Gribbestad IS; Bathen TF
NMR Biomed; 2012 Nov; 25(11):1271-9. PubMed ID: 22407957
[TBL] [Abstract][Full Text] [Related]
12. E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer.
Chen HA; Chang YW; Tseng CF; Chiu CF; Hong CC; Wang W; Wang MY; Hsiao M; Ma JT; Chen CH; Jiang SS; Wu CH; Hung MC; Huang MT; Su JL
Ann Surg Oncol; 2015 Mar; 22(3):889-98. PubMed ID: 25212833
[TBL] [Abstract][Full Text] [Related]
13. Glutamate enrichment as new diagnostic opportunity in breast cancer.
Budczies J; Pfitzner BM; Györffy B; Winzer KJ; Radke C; Dietel M; Fiehn O; Denkert C
Int J Cancer; 2015 Apr; 136(7):1619-28. PubMed ID: 25155347
[TBL] [Abstract][Full Text] [Related]
14. Impact of intratumoral heterogeneity on the metabolic profiling of breast cancer tissue using high-resolution magic angle spinning magnetic resonance spectroscopy.
Choi JS; Yoon D; Han K; Koo JS; Kim S; Kim MJ
NMR Biomed; 2022 Jun; 35(6):e4682. PubMed ID: 34959254
[TBL] [Abstract][Full Text] [Related]
15. Differences in elongation of very long chain fatty acids and fatty acid metabolism between triple-negative and hormone receptor-positive breast cancer.
Yamashita Y; Nishiumi S; Kono S; Takao S; Azuma T; Yoshida M
BMC Cancer; 2017 Aug; 17(1):589. PubMed ID: 28851309
[TBL] [Abstract][Full Text] [Related]
16. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
17. Triple-negative breast cancer is not associated with increased likelihood of nodal metastases.
Gangi A; Mirocha J; Leong T; Giuliano AE
Ann Surg Oncol; 2014 Dec; 21(13):4098-103. PubMed ID: 25155393
[TBL] [Abstract][Full Text] [Related]
18. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance metabolic profiling of estrogen receptor-positive breast cancer: correlation with currently used molecular markers.
Choi JS; Yoon D; Koo JS; Kim S; Park VY; Kim EK; Kim S; Kim MJ
Oncotarget; 2017 Sep; 8(38):63405-63416. PubMed ID: 28969000
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical signaling pathways of triple negative and triple positive breast cancers: What is new?
Elsers DA; Masoud EM; Kamel NAMH; Ahmed AM
Ann Diagn Pathol; 2021 Dec; 55():151831. PubMed ID: 34634762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
